%D8%A5%D9%8A%D9%86%D8%B2%D8%A7%D9%84%D9%88%D8%AA%D8%A7%D9%85%D9%8A%D8%AF%D8%A7%D9%85%E2%80%8C%D8%AF%DB%8C%E2%80%8C%D9%88%DB%8C%DB%B3%DB%B1%DB%B0%DB%B0Category:EnzalutamideEnzalutamidEnzalutamideEnzalutamida%D8%A7%D9%85%E2%80%8C%D8%AF%DB%8C%E2%80%8C%D9%88%DB%8C%DB%B3%DB%B1%DB%B0%DB%B0EnzalutamideEnzalutamide%E3%82%A8%E3%83%B3%E3%82%B6%E3%83%AB%E3%82%BF%E3%83%9F%E3%83%89EnzalutamidEnzalutamidEnzalutamidQ1996756
about
P2176
P3781
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approachesIncreased survival with enzalutamide in prostate cancer after chemotherapyMDV3100 for the treatment of prostate cancer.ARN-509: a novel antiandrogen for prostate cancer treatmentAbiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.Methoxychalcone inhibitors of androgen receptor translocation and function.Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.Novel options for the treatment of castration-resistant prostate cancer.Androgen deprivation therapy as primary treatment for prostate cancer.Therapeutic options for advanced prostate cancer: 2011 update.Overcoming castration resistance in prostate cancer.Current and emerging treatments in the management of castration-resistant prostate cancer.Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancerNovel and bone-targeted agents for CRPC.[Therapy of castration-resistant prostate cancer]Q57133737Q57134465Q57135360[How should hormone therapy for castration-resistant prostate cancer be continued?]
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Enzalutamid
@de
Enzalutamid
@sh
Enzalutamid
@sr
Enzalutamide
@en-ca
Enzalutamide
@en-gb
MDV3100
@it
enzalutamid
@pl
enzalutamida
@es
enzalutamide
@en
enzalutamide
@fr
type
label
Enzalutamid
@de
Enzalutamid
@sh
Enzalutamid
@sr
Enzalutamide
@en-ca
Enzalutamide
@en-gb
MDV3100
@it
enzalutamid
@pl
enzalutamida
@es
enzalutamide
@en
enzalutamide
@fr
altLabel
Enzalutamide
@en
Enzulatamide
@fr
MDV 3100
@en
MDV-3100
@en
MDV3100
@en
Xtandi®
@en
ام دی وی3100
@fa
ام دی وی۳۱۰۰
@fa
prefLabel
Enzalutamid
@de
Enzalutamid
@sh
Enzalutamid
@sr
Enzalutamide
@en-ca
Enzalutamide
@en-gb
MDV3100
@it
enzalutamid
@pl
enzalutamida
@es
enzalutamide
@en
enzalutamide
@fr